{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-25-000072","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.851319+00:00","generated_at":"2026-05-19T21:51:57.115153+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"high","headline":"Acumen shareholders elect three Class I directors, ratify EY as auditor","bullets":["Elected Kimberlee C. Drapkin, Jeffrey Ives, and Sean Stalfort as Class I directors until 2028 with ~30M votes each; ~17.5M broker non-votes.","Ratified Ernst & Young as independent auditor for FY2025: 51.4M for, 118,735 against, 35,514 abstain.","Approximately 85% of outstanding shares (51.5M of 60.6M) were present or represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-25-000072","json":"https://secwatch.observer/filing/0001576885-25-000072.json","markdown":"https://secwatch.observer/filing/0001576885-25-000072.md","text":"https://secwatch.observer/filing/0001576885-25-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000072/0001576885-25-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000072/abos-20250604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:51:57.115153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}